International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com,
announced today that the first new topical skin care products of its
subsidiary, Lifeline Skin Care, are now available to the general public
within the United States at http://www.lifelineskincare.com.
Lifeline Skin Care's first two products consist of a Defensive Day
Moisture Serum and Recovery Night Moisture Serum. Previously, these
breakthrough serums, containing extracts from "parthenogenetic" stem
cells, were available only to individuals and organizations formerly
identified and selected for their interest in innovative approaches to
skin care.
According to Lifeline Skin Care CEO, Dr. Ruslan Semechkin, "Because the
quality products Lifeline Skin Care offers are experiencing strong
demand and the human stem cell extracts require innovative manufacturing
processes, we chose to develop our sales channels gradually and
incrementally. We are very pleased with the customer feedback from our
first limited launch and are delighted to now be able to expand
production and make the products available to the general public within
the US."
Purchases that could previously be made only by phone, can now be made
directly through the company's website, www.lifelineskincare.com.
"Enabling electronic order processing though our website provides the
benefit of both lowering our transaction costs and increasing our
scalability, while simultaneously simplifying the ordering process for
our customers," said ISCO VP, Dr. Simon Craw.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells from unfertilized oocytes (eggs). These proprietary cells
avoid ethical issues associated with use or destruction of viable human
embryos and, unlike most other major stem cell types, can be immune
matched and be a source of therapeutic cells with minimal rejection
after transplantation into hundreds of millions of individuals of
differing racial groups. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary, Lifeline Cell Technology, and is developing a line of
cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is
advancing novel human stem cell-based therapies where cells have been
proven to be efficacious but traditional small molecule and protein
therapeutics have not. More information is available on ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated developments, product introduction
plans and related support, the potential benefits of planned products,
anticipated sales growth for recently introduced products, and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to
obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care,
anti-aging
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 1-760-940-6383 kaldrich@intlstemcell.com or Lifeline
Skin Care, Inc. Ruslan Semechkin, PhD, President & CEO Vice
President, ISCO ras@intlstemcell.com |